September 2024

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY® and TECVAYLI® monotherapies RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b RedirecTT-

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: